Abstract 5635
Background
A cancer diagnosis often causes an emotional impact with signs of anxiety, uncertainty and subjective discomfort. It´s necessary to identify and assess emotional discomfort to offer quality treatment articulated around the patient and his / her demand. The design of a questionnaire that is easy to use and understand, allows the detection of patients susceptible to referral to the Psycho-oncology Unit (POU).
Methods
- Prepare a PAQ that includes: Evaluation of emotional distress assisted by visual analogue scales (VAS); Modified Gijón scale (sociofamilar assessment scale); previous use of psychoactive drugs - Include PAQ in the first nursing visit - Quick referral to POU - Interview with psycho-oncology nurse - Valuation, diagnosis and treatment planning by POU - Data recording - Data analysis.
Results
Patients with a positive PAQ are referred to the POU where the liaison nurse performs an interview with the patient and / or family. The nurse collects data on psychobiography, oncological disease, psychic sphere, frequent affections, previous contacts with psychologists / psychiatrists and treatments with psychoactive drugs. The POU will offer the patient the most appropriate resource for their needs (Psychotherapy, Psychopharmaceuticals, and Social Work Service).
Conclusions
The inclusion of the PAQ in the first visit of nursing allows the detection and early treatment of disorders in the psychosocial area. We achieve an optimal use of resources, a greater adherence to the proposed oncological treatment, alleviate problems that are found throughout the oncological treatment and improve the quality of life of our patients by reducing emotional discomfort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract